Nikki Martin on LUNGevity’s “No One Missed Campaign” Focusing on Biomarker Testing Access

CancerNetwork® spoke with Nikki Martin of the LUNGevity Foundation regarding the “No One Missed” campaign working to provide education and awareness to patients with lung cancer.

CancerNetwork® recently spoke with Nikki Martin, director of Precision Medicine Initiatives at LUNGevity Foundation, regarding the recently launched No One Missed campaign.

The campaign focuses on helping patients gain access to valuable comprehensive biomarker testing, which can reveal the presence of driver mutations that are key in the treatment decision-making process.

“The No One Missed campaign is the latest evolution of our awareness and education programs for really targeting patients, but I can see how ultimately it could also become a provider-focused education and awareness campaign,” explained Martin. “what makes No One Missed unique is that it’s much broader than our previous education and awareness efforts. It’s a community-led program, so it’s not just LUNGevity Foundation running it, but we’re doing a lot more to pull in other stakeholders within the lung cancer ecosystem.”

LUNGevity Foundation is a nonprofit organization focusing on accelerating research and developing programs to remove barriers for patients with lung cancer accessing the necessary resources and care.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.
Experts on lung cancer
Related Content